Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JP-1366 + aceclofenac
- Development stage
- Unknown
- Lead developer
- Onconic Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JP-1366 + aceclofenac is a combination of two pharmaceutical agents. JP-1366 is a novel, potent potassium-competitive acid blocker (P-CAB) that selectively and dose-dependently inhibits gastric H+/K+-ATPase, leading to suppression of gastric acid secretion. It has demonstrated strong efficacy in preclinical models for gastroesophageal reflux disease (GERD) and gastric ulcers, showing greater potency than TAK-438 (vonoprazan) in some studies. Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID), structurally related to diclofenac, used primarily for the relief of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Aceclofenac acts by inhibiting both COX isoforms but displays higher selectivity for COX‑2 over COX‑1, which may confer improved gastrointestinal tolerability compared to other NSAIDs[1][3][5][6].
- Brand names
- HifenacClanza CR
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on JP-1366 + aceclofenac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JP-1366 + aceclofenac.